Loading...

XNCR XENCOR INC Other Situations 8-K Filing

XNCR

XNCR

XENCOR INC

(XNCR)

2025 8-K

Show Summary

Summary

Appointing Directors

Clinical Updates

Director Appointment

Financial Results

Financial Restatement

Financial Update

Q3 Financial Results

Public Offering

Clinical Updates

Results of Operations and F...

Annual Meeting of Stockholders

Earnings Report

Resignation and Appointment...

Results of Operations and F...

Collaboration Agreement wit...

Results of Operations and F...

Departure of CFO

Appointment of Director

Results of Operations and F...

Annual Meeting of Stockholders

Results of Operations and F...

Resignation and Appointment

Regulation FD Disclosure

Sales Agreement

Results of Operations and F...

External Links:

On April 29, 2025, Xencor Inc. announced interim results from its Phase 1 study of XmAb942 (Xtend™ TL1A) and shared preclinical data regarding the XmAb TL1A x IL23p19 program during a conference call.

AI Assistant

XENCOR INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.